11 Best Guru Stocks to Buy According to Wall Street Analysts

Page 9 of 10

2. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

Number of Hedge Fund Holders: 36

Average Upside Potential: 166.09%

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a late-stage biotech company working on treatments for metabolic diseases. The company is developing obicetrapib, a pill aimed at lowering bad cholesterol and potentially treating Alzheimer’s, with clinical trials currently in progress. It is one of the best Guru stocks to buy, ranking 2nd on our list.

On February 27, Scotiabank analyst George Farmer maintained a Sector Outperform rating on NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) with a price target of $52, up from $47. The company’s lead drug, obicetrapib, shows strong results in lowering bad cholesterol. The analyst observed that with $834 million in cash, extended patent protection to 2043, and regulatory filings expected in late 2025, the company is well-positioned for growth and potential acquisition.

By the end of 2024, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)’s cash and marketable securities had grown to $834.2 million, up from $340.5 million in 2023. This increase came from public equity offerings, hitting a clinical milestone, and exercising warrants and options, although some of the cash went into R&D and higher administrative expenses. The company earned $45.6 million in revenue during 2024, a big leap from $14.1 million in 2023, mostly due to reaching a clinical milestone and receiving reimbursement for development costs. NewAmsterdam reported a net loss of $241.6 million for 2024, up from $176.9 million last year, mainly due to non-cash losses linked to changes in the value of their derivative liabilities.

According to Insider Monkey’s fourth quarter database, 36 hedge funds were bullish on NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), compared to 29 funds in the preceding quarter.

Page 9 of 10